Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Adding More Pediatric Data To Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA divisions will be more aggressive in requiring pediatric data be included in labeling following recommendation by Office of New Drugs Director Jenkins. However, the added language in labeling will not necessarily clarify whether a drug is safe for use in children, Office of Pediatric Therapeutics Director Murphy notes.

You may also be interested in...



Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis

FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.

Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis

FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.

FDA Approves Antidepressant "Black Box" Class Labeling

The revised labeling should be available on manufacturers' web pages within two weeks and on all products within 30 days, FDA says. Medication Guides should be available to pharmacists by Jan. 31, the agency says.

Related Content

Topics

UsernamePublicRestriction

Register

PS061548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel